1. Home
  2. CHH vs SRRK Comparison

CHH vs SRRK Comparison

Compare CHH & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Choice Hotels International Inc.

CHH

Choice Hotels International Inc.

HOLD

Current Price

$100.58

Market Cap

4.4B

ML Signal

HOLD

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$45.10

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHH
SRRK
Founded
1939
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.6B
IPO Year
1997
2018

Fundamental Metrics

Financial Performance
Metric
CHH
SRRK
Price
$100.58
$45.10
Analyst Decision
Hold
Strong Buy
Analyst Count
13
11
Target Price
$112.92
$55.40
AVG Volume (30 Days)
512.4K
1.4M
Earning Date
05-07-2026
03-03-2026
Dividend Yield
1.16%
N/A
EPS Growth
27.42
N/A
EPS
7.90
N/A
Revenue
$1,596,793,000.00
N/A
Revenue This Year
$66.74
N/A
Revenue Next Year
$0.49
$550.26
P/E Ratio
$12.56
N/A
Revenue Growth
0.75
N/A
52 Week Low
$84.04
$22.71
52 Week High
$136.45
$49.82

Technical Indicators

Market Signals
Indicator
CHH
SRRK
Relative Strength Index (RSI) 48.78 53.21
Support Level $99.40 $41.07
Resistance Level $103.62 $48.29
Average True Range (ATR) 3.01 2.39
MACD 0.31 0.33
Stochastic Oscillator 79.53 70.39

Price Performance

Historical Comparison
CHH
SRRK

About CHH Choice Hotels International Inc.

At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

Share on Social Networks: